相关实验视频

Updated: Apr 27, 2026

Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing

Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing

Published on: July 5, 2019

病例报告: 一名患有e8a2 BCR::ABL1融合转录的慢性髓性白血病患者被弗鲁马提尼布成功治疗

Shanfeng Hao¹, Yao Zhang¹, Qing Shao¹

¹Department of Hematology, Tianjin Medical University General Hospital, Tianjin, China.

Frontiers in oncology

|October 6, 2025

概括

这项研究突出了慢性髓性白血病 (CML) 中罕见的e8a2 BCR::ABL1转录变体. 尽管面临挑战,但该患者通过flumatinib实现了缓解,证明了非典型CML病例的治疗疗效.

科学领域:

血液学血液学血液学
在瘤学瘤学.
分子生物学分子生物学

背景情况:

慢性髓性白血病 (CML) 通常涉及常见的BCR::ABL1转录 (b2a2/e13a2,b3a2/e14a2).
一小部分的CML患者 (约. 2%) 存在非典型的BCR::ABL1断点.
鉴定非典型的转录是至关重要的,因为它们通常对氨酸激酶抑制剂 (TKI) 治疗有反应.

研究的目的:

报告一种罕见的e8a2 BCR::ABL1转录变异的CML病例.
描述临床表现,包括同时出现的缺铁性贫血.
评估这种特定的CML亚型中对Flumatinib的治疗反应.

主要方法:

一个患有e8a2 BCR::ABL1转录的CML患者的病例报告.
同诊断难以纠正的缺铁性贫血.
用弗卢马替尼 (flumatinib) 治疗,弗卢马替尼是一种氨酸激酶抑制剂.

主要成果:

患者在Flumatinib治疗1个月内实现了完全的血液缓解.
在3个月后观察到完全的细胞遗传缓解.
经过6个月的治疗,主要的分子缓解得到了实现.

结论:

非典型的BCR::ABL1转录变体,如e8a2,可以有效地用像flumatinib这样的TKI治疗.
早期识别和适当的治疗是管理CML的关键,即使是罕见的转录类型.
弗鲁马替尼在患有不常见的BCR::ABL1变异的CML患者中实现深层分子反应方面表现出有效性.

关键词:

慢性骨髓性白血病慢性骨髓性白血病 e8a2 BCR::ABL1 的转录弗鲁马丁尼布 (flumatinib) 是一种药物.缺铁性贫血是因为缺铁性贫血.铁氨酸激酶抑制剂治疗的治疗方法

更多相关视频

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on: October 17, 2025

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...